Introduction
Acute myeloid leukemia (AML) is a clonal hematopoietic disorder characterized by genetic and epigenetic alterations leading to a block in differentiation and accumulation of leukemic blasts in blood and bone marrow (BM). 1 Epigenetic silencing of genes involved in hematopoietic differentiation plays a critical role in myeloid leukemogenesis. 2, 3 Gene silencing caused by DNA hypermethylation can be reversed pharmacologically by inhibition of DNA methyltransferases (DNMTs) using azanucleosides such as decitabine. 2, 3 Our group recently reported a 47% complete response rate with a 10-day regimen of low dose decitabine as a single agent in previously untreated older AML patients (>60 years). 4 Although patients' survival was not significantly better than that obtained with more intensive chemotherapy regimens (i.e., "7+3"), the single agent decitabine regimen was well tolerated and had low toxicity.
These results therefore suggest the opportunity to capitalize on this relatively non-toxic treatment and make it more effective by incorporating this compound into novel molecularly targeted approaches. Exportin 1 (XPO1) is a nuclear receptor exporter involved in the active transport of a number of cargo proteins, including transcription factors and tumor suppressor proteins (TSP; i.e., p53 and p27), cell-cycle regulators (i.e., Cdkn1a) and RNA molecules. 5, 6 Recent data indicate that TSP can be exported from the nucleus and thereby inactivated in cancer by hyperactive nuclear export. 7 Indeed, XPO1 over-expression has been reported in several solid tumors and leukemias, including AML and it is associated with worse outcome.
, 9
Thus, XPO1 inhibition may result in increased levels of active TSP and orally bioavailable selective inhibitors of nuclear export (SINE) that covalently bind and inhibit XPO1 are being explored as a novel therapeutic approach
For personal use only. on April 13, 2017. by guest www.bloodjournal.org From in solid tumors and hematologic malignancies. 10, 11 Our group recently reported the antileukemic activity of SINEs in vitro and in vivo in AML. 11 SINEs displayed potent antiproliferative properties at submicromolar concentrations with regard to apoptosis, cellcycle arrest and myeloid differentiation in AML cell lines and patient blasts. 11 Finally, using the FLT3-ITD positive MV4-11 xenograft murine model, we show that treatment of mice with oral SINE significantly prolongs survival of leukemic mice. 11 These preclinical studies have supported the development of a large Phase 1 clinical trial with selinexor (last generation SINE) in patients with advanced hematological malignancies, including AML. Preliminary data indicate that selinexor is well tolerated, safe and active in refractory/relapsed AML patients. 12 However, considering the molecular complexity of AML, it is unlikely that this disease can be cured with monotherapy and therefore we asked whether adding an already established effective drug such as decitabine to selinexor will enhance or improve its anti-leukemic effects in AML.
Methods

Cell lines
AML cell lines, MV4-11, MOLM-13 and OCI-AML3 were purchased from DSMZ, Germany. All cell lines were cultured in RPMI supplemented with 10% FBS and 100U/mL penicillin and 100ug/mL streptomycin. 
Results and Discussion
We initially treated two AML cell lines (OCI-AML3 and MV4-11) concomitantly with decitabine and selinexor at two-fold dilutions of their individual IC 50 values, and measured cell proliferation using the WST-1 assay at 48 hours. The combination index (CI) was calculated according to the Chou-Talalay method. 13 The CIs for the different combinations were around 1 or above 1, indicating no synergy (Supplemental Figure 1 ).
Since decitabine is a cell-cycle dependent nucleoside analogue, we reasoned that these results could be explained by the cell cycle arrest induced by selinexor. Next we asked whether sequential treatment would be more effective. For this approach, we used the WST-1 assay where cells were exposed to decitabine (IC 50 2 fold dilutions, 4uM -250 nM) for 24hrs followed by selinexor (IC 50 2 fold dilutions, 400nm -25nM) for 24hrs ( Supplemental Table S1 ). This sequential treatment resulted in CI values below 1, indicating synergy as calculated by the Chou-Talalay method ( Figure 1A and Supplemental Table S2 ). These results were validated using a third AML cell line, Figure 2A ). In addition, a significant induction of apoptosis was observed (Supplemental Figure 3 ).
MOLM-13 (Supplemental
For personal use only. on April 13, 2017. by guest www.bloodjournal.org From Thus, we hypothesized that these effects could be mediated by the re-expression of a subset of nuclear tumor suppressors (i.e., CDKN1A (p21) and FOXO3A) 14,15 that are epigenetically silenced via DNA methylation and whose cytoplasmic-nuclear trafficking is regulated by XPO1 6 ( Figure 1B ). Supporting this hypothesis we observed that decitabine treatment increased CDKN1A and FOXO3A expression levels at both the RNA and protein level in the AML cell lines OCI-AML3, MV4-11 and MOLM-13 ( Figure 1C and Supplemental Figure 2B ). These two genes were also found up-regulated in cell lines and BM samples from AML patients treated with hypomethylation agents. 14, 15 To delineate further the mechanism of this enhanced anti-leukemic activity, we overexpressed CDKN1A using a lentiviral vector in both OCI-AML3 and MV4-11 cells (to mimic the priming effect of decitabine) and subsequently treated them with selinexor.
Similar to the decitabine/selinexor treatment, ectopic CDKN1A and FOXO3A overexpression in OCI-AML3 and MV4-11 cells followed by selinexor treatment at lower than IC 50 values resulted in significantly decreased cellular proliferation ( Figure 1D Figure 6 ). We then tested the efficacy of the combination in vivo using an established xenograft mouse model of AML. MV4-11 cells obtained from spleens of primary MV4-11 xenografts were transplanted into non-obese diabetic/severe combined immunodeficient (NOD-SCID) gamma (NSG) mice via tail vein. Mice were monitored closely for clinical signs of leukemia as described in methods. One week after leukemia cell injection, the mice were given either vehicle control, decitabine alone (0.4mg/kg, intra peritoneal (i.p.) twice weekly (BIW), selinexor alone (20mg/kg, oral
For personal use only. on April 13, 2017. by guest www.bloodjournal.org From gavage, BIW), selinexor alone (10mg/kg, oral gavage, BIW) or decitabine (0.4mg/kg i.p. BIW, given Mondays and Tuesdays followed by selinexor (10mg/kg, oral gavage BIW), given on Wednesdays and Fridays. All treatments were given for three weeks after leukemia cell injection. Single agent selinexor at 10mg/kg or decitabine alone had no effect in prolonging the survival of mice with respect to the control mice (vehicle control). In contrast, decitabine (0.4mg/kg) followed by selinexor (10mg/kg), significantly increased mice survival even when compared with selinexor alone at higher dose (20mg/kg; 47 vs. 36.5 days, p<0.008; Figure 2A ). On day 25, separate cohorts of vehicle and drug treated mice were sacrificed; spleens harvested and picture taken for comparative study of spleen size. The decitabine-selinexor combination treated mice exhibited smaller spleens size than the other groups and controls (Supplemental Figure   7 ). Finally, we validated the efficacy of the sequential drug treatment in vitro using primary AML blasts. In Supplementary Table S3 we report patient's cytogenetic and molecular characteristics and concentrations of decitabine and selinexor treatments. The initial priming by decitabine followed by selinexor treatment significantly decreased the percentage of live cells compared to either decitabine treatment alone ( Figure 2B , p=0.005) or selinexor treatment alone ( Figure 2B , p=0.02) as measured by apoptosis.
In summary, we show here that decitabine priming increased the anti-leukemic effects of selinexor in AML in vitro and in vivo. It should be underscored that the decitabine priming enhanced the antileukemic activity of selinexor at lower doses compared to the treatment of selinexor alone at higher doses. This is relevant to patients since it is then possible to use lower doses of selinexor to increase tolerability without compromising the Combination index (CI) plots of decitabine (DAC) with selinexor. The effect of the combinations was assessed by WST-1 assay after initial priming with DAC (24hrs) followed by selinexor treatment for 24hrs. The doses for both drugs were chosen according to their individual IC 50 (2 fold dilutions), which were determined using WST-1 assay (Supplemental Table 1 ). Since DAC is given for 48 hours, we determined the DAC IC 50 at 48 hours. The IC 50 for selinexor was determined at 24 hours since the treatment with this drug was shorter. The effects of the combinations were calculated using 
